## Edgar Filing: BIOGEN INC. - Form 4


BIOGEN IN Form 4	NC.									
February 17	7, 2017									
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									PPROVAL 3235-0287	
Check this box Expires:							urs per			
(Print or Type	Responses)									
1. Name and Address of Reporting Person <sup>*</sup> Ehlers Michael D				er Name <b>an</b>	<b>d</b> Ticker or	Trading	5. Relationship of Reporting Person(s) to Issuer			
			BIOGEN INC. [BIIB]				(Check all applicable)			
(Last) (First) (Middle) BIOGEN INC., 225 BINNEY ST.			<ul><li>3. Date of Earliest Transaction</li><li>(Month/Day/Year)</li><li>02/15/2017</li></ul>				Director 10% Owner Officer (give title Other (specify below) below) EVP, Research and Development			
	4. If Amendment, Date Original			al	6. Individual or Joint/Group Filing(Check					
CAMBRII	DGE, MA 02142		Filed(Mo	onth/Day/Yea	ır)			y One Reporting P 7 More than One R		
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deeme Execution I any (Month/Day	Date, if	3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or Code V Amount (D) Pr		(A) or of (D) 4 and 5) (A)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Re	port on a separate line	e for each cla	ss of sec							
					-	-	spond to the colle	ection of	SEC 1474	

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onof Derivative	Expiration Date	Underlying Securities	Ε
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	S

## Edgar Filing: BIOGEN INC. - Form 4



## **Reporting Owners**

Reporting Owner Name / Address							
	Director 10% Owner		Officer	Other			
Ehlers Michael D BIOGEN INC. 225 BINNEY ST. CAMBRIDGE, MA 02142			EVP, Research and Development				
Signatures							
Suzanne Murray, Attorney in Fact for Michael D. Ehlers			02/17/2017				
<u>**</u> Signature of Reportin	g Person		Date				

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date.

(1) The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.